Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 2.59 -0.01 (-0.38%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel ...
This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January.
Related articles »  
Pluristem Therapeutics Inc. (PSTI): The Bull Case For Pluristem Therapeutics
Now, Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has a proprietary technology that creates a natural seeming environment for cell culture, making them more robust while also less expensive to generate.
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Mesoblast Is No Match For Pluristem's IP ...
Last week, Pluristem Therapeutics Inc. (NASDAQ:PSTI) won a method of use patent in Australia for its PLX cells in ischemia, where obstruction of blood vessels to an organ causes tissue death.
Related articles »  
Pluristem Therapeutics Inc. (PSTI) news: Pluristem's Preeclampsia Effort ...
The power of the placenta rings truer than ever in an upcoming therapeutic indication planned by Pluristem Therapeutics, Inc. (NASDAQ:PSTI) using PLX cell therapy for treating pregnant women with preeclampsia, a leading cause of maternal and infant ...
Related articles »  
Pluristem rebuffs patent challenge (PSTI)
Pluristem Therapeutics (NASDAQ:PSTI) fends off a challenge from an unnamed cell therapy company to its European patent No.
Pluristem Therapeutics Lifted to "Outperform" at Zacks (PSTI)  WKRB News
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Pluristem's Positive Data Could Open ...
In a few short weeks, Pluristem Therapeutics (NASDAQ:PSTI) will announce landmark data using its PLX cell therapy on gluteal muscle injury that results from hip replacement surgery.
United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's ...
Pluristem Therapeutics Inc. PSTI, -0.38% (tase:PLTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase ...
Phase I Trial of Pluristem's PLX-PAD Cells for Pulmonary Arterial ...  Pulmonary Hypertension News
Related articles »  
Pluristem Therapeutics COO Acquires $28820 in Stock (PSTI)
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) COO Yaky Yanay bought 11,000 shares of the company's stock on the open market in a transaction dated Tuesday, November 11th. The shares were purchased at an average price of ...
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Celgene's And Osiris' IP Positions ...
Intellectual property is an invaluable asset for a biotechnology company, where a large percentage of operating costs go to research and development in hopes of creating the next big drug.
Related articles »